Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVRd followed by ciltacabtagene autoleucel versus DVRd followed by autologous stem cell transplant in transplant-eligible newly diagnosed multiple myeloma
2023-507632-20-00Phase 3Authorised
- Sponsor
- European Myeloma Network
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoints: Progression-free survival and Sustained MRD-negative complete response. Planned start May 2024; status: authorised.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507632-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507632-20-00.